Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults

Phase 1 Not yet recruiting 68 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single and multiple intravenous ascending dose clinical study to evaluate the safety, tolerability, PK, immunogenicity, and biomarker characteristics of GenSci155 after a single or multiple intravenous injection in healthy Chinese adult trial participants.

Timeline

Start: 2026-07-28
Primary completion: 2027-04-16
Completion: 2027-07-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GenSci155	Unknown	—	Intravenous

Indications

No indication recorded.